New and emerging disease modifying therapies for multiple sclerosis

Shiv Saidha, Christopher Eckstein, Peter Calabresi

Research output: Contribution to journalArticle

Abstract

Several disease-modifying drugs (DMDs) are currently approved for the treatment of multiple sclerosis (MS). Recently, there has been increased identification and development of potential new treatments that may modulate the MS disease process, including oral therapies. Many of the newly approved MS therapies, as well as those in ongoing clinical trials, have the advantage of improved efficacy and/or being oral and more convenient, as compared to conventional injectable first-line MS therapies. However, many of these new and emerging MS treatments are known to be associated with serious adverse events, some of which may be potentially life threatening. Of additional concern, there is limited experience and long-term safety data for many of these drugs, and thus the true potential for complications associated with these agents remains ambiguous. With an anticipated explosion in the artillery of available MS therapies in the near future, neurologists will need to carefully weigh drug efficacy, convenience, safety, and tolerability when making therapeutic decisions. In this review, we describe the known mechanisms of action, efficacy, and side-effect profiles of new and emerging MS DMDs.

Original languageEnglish (US)
Pages (from-to)117-137
Number of pages21
JournalAnnals of the New York Academy of Sciences
Volume1247
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Multiple Sclerosis
Pharmaceutical Preparations
Therapeutics
Explosions
Safety
Therapy
Decision Making
Clinical Trials
Drugs
Injections
Efficacy

Keywords

  • Alemtuzumab
  • Anti-CD20
  • BG12
  • Cladribine
  • Daclizum b
  • Fingolimod
  • Laquinimod
  • Monoclonal antibodies
  • Multiple sclerosis
  • Teriflunomide

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

New and emerging disease modifying therapies for multiple sclerosis. / Saidha, Shiv; Eckstein, Christopher; Calabresi, Peter.

In: Annals of the New York Academy of Sciences, Vol. 1247, No. 1, 01.2012, p. 117-137.

Research output: Contribution to journalArticle

@article{14e81e111f59409ca07e9f3aa3d43e33,
title = "New and emerging disease modifying therapies for multiple sclerosis",
abstract = "Several disease-modifying drugs (DMDs) are currently approved for the treatment of multiple sclerosis (MS). Recently, there has been increased identification and development of potential new treatments that may modulate the MS disease process, including oral therapies. Many of the newly approved MS therapies, as well as those in ongoing clinical trials, have the advantage of improved efficacy and/or being oral and more convenient, as compared to conventional injectable first-line MS therapies. However, many of these new and emerging MS treatments are known to be associated with serious adverse events, some of which may be potentially life threatening. Of additional concern, there is limited experience and long-term safety data for many of these drugs, and thus the true potential for complications associated with these agents remains ambiguous. With an anticipated explosion in the artillery of available MS therapies in the near future, neurologists will need to carefully weigh drug efficacy, convenience, safety, and tolerability when making therapeutic decisions. In this review, we describe the known mechanisms of action, efficacy, and side-effect profiles of new and emerging MS DMDs.",
keywords = "Alemtuzumab, Anti-CD20, BG12, Cladribine, Daclizum b, Fingolimod, Laquinimod, Monoclonal antibodies, Multiple sclerosis, Teriflunomide",
author = "Shiv Saidha and Christopher Eckstein and Peter Calabresi",
year = "2012",
month = "1",
doi = "10.1111/j.1749-6632.2011.06272.x",
language = "English (US)",
volume = "1247",
pages = "117--137",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - New and emerging disease modifying therapies for multiple sclerosis

AU - Saidha, Shiv

AU - Eckstein, Christopher

AU - Calabresi, Peter

PY - 2012/1

Y1 - 2012/1

N2 - Several disease-modifying drugs (DMDs) are currently approved for the treatment of multiple sclerosis (MS). Recently, there has been increased identification and development of potential new treatments that may modulate the MS disease process, including oral therapies. Many of the newly approved MS therapies, as well as those in ongoing clinical trials, have the advantage of improved efficacy and/or being oral and more convenient, as compared to conventional injectable first-line MS therapies. However, many of these new and emerging MS treatments are known to be associated with serious adverse events, some of which may be potentially life threatening. Of additional concern, there is limited experience and long-term safety data for many of these drugs, and thus the true potential for complications associated with these agents remains ambiguous. With an anticipated explosion in the artillery of available MS therapies in the near future, neurologists will need to carefully weigh drug efficacy, convenience, safety, and tolerability when making therapeutic decisions. In this review, we describe the known mechanisms of action, efficacy, and side-effect profiles of new and emerging MS DMDs.

AB - Several disease-modifying drugs (DMDs) are currently approved for the treatment of multiple sclerosis (MS). Recently, there has been increased identification and development of potential new treatments that may modulate the MS disease process, including oral therapies. Many of the newly approved MS therapies, as well as those in ongoing clinical trials, have the advantage of improved efficacy and/or being oral and more convenient, as compared to conventional injectable first-line MS therapies. However, many of these new and emerging MS treatments are known to be associated with serious adverse events, some of which may be potentially life threatening. Of additional concern, there is limited experience and long-term safety data for many of these drugs, and thus the true potential for complications associated with these agents remains ambiguous. With an anticipated explosion in the artillery of available MS therapies in the near future, neurologists will need to carefully weigh drug efficacy, convenience, safety, and tolerability when making therapeutic decisions. In this review, we describe the known mechanisms of action, efficacy, and side-effect profiles of new and emerging MS DMDs.

KW - Alemtuzumab

KW - Anti-CD20

KW - BG12

KW - Cladribine

KW - Daclizum b

KW - Fingolimod

KW - Laquinimod

KW - Monoclonal antibodies

KW - Multiple sclerosis

KW - Teriflunomide

UR - http://www.scopus.com/inward/record.url?scp=84856432895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856432895&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2011.06272.x

DO - 10.1111/j.1749-6632.2011.06272.x

M3 - Article

C2 - 22224673

AN - SCOPUS:84856432895

VL - 1247

SP - 117

EP - 137

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -